acetyl- glycyl- valyl- allo- isoleucyl- seryl- glutaminyl- isoleucyl- arginyl- prolyl- cysteinamide

05/28/2015 - "These findings indicate that the new peptide ABT-898 ameliorates inflammation and angiogenesis and might be a therapeutic alternative in IBD and inflammatory diseases."
05/28/2015 - "Thrombospondin peptide ABT-898 inhibits inflammation and angiogenesis in a colitis model."

05/28/2015 - "To evaluate the efficacy of the improved thrombospondin mimetic peptide ABT-898 in a murine model of ulcerative colitis. "

10/01/2011 - "Results from this study show that ABT-898 is capable of regressing established ovarian tumors in an animal model of the disease. "
10/01/2011 - "Ovarian tumors were induced and ABT-898 treatment was initiated at time points that were representative of late stages of the disease to study tumor regression. "
10/01/2011 - "ABT-898 induced tumor regression and reduced the morbidity of treated animals compared with controls. "
10/01/2011 - "ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer."
10/01/2011 - "In this study, we evaluated the ability of the thrombospondin-1 mimetic peptide, ABT-898, to regress established, late-stage tumors in a mouse model of human EOC. "

08/01/2012 - "Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1)."
08/01/2012 - "In the present study, we explored the potential effect of ABT-510 and ABT-898 on experimental prolactinomas induced by chronic diethylstilbestrol (DES) treatment in female rats. "

01/01/2015 - "ABT-898 did not affect estrous cycling or pregnancy parameters including litter size across generations and offspring weight gain. "